Perioperative treatment
Phase 2Small molecule
Perioperative treatment is one of 55 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
54
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Acupan
YYonsei University
Phase 3
Taxotere
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Perioperative treatment
PPeking University Cancer Hospital & Institute
Phase 2
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perioperative treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details